SBIR/STTR Research Award

Targeting endogenous sialidases for treatment of endotoxic shock

Award identifier 2f5a8c599f9087d1cf87cf44391b62213b236a9306b726c1912e476738f82390Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$395,408

Program and phase

SBIR · Phase I

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Oncoimmune Inc
Proposal award date
2014-08-01
Contract end date
2016-07-31
UEI
G8WAHQ82DVC4
Solicitation number
PA10-122
Topic code
NIAID

Research abstract

DESCRIPTION provided by applicant Despite the advance of antibiotics sepsis remains a major challenge to human health as both survival and incidence of severe sepsis have been largely unchanged in the last two decades It is therefore important to develop new therapeutic approaches We have recently reported that bacterial sialidases may serve as therapeutic targets for polybacterial sepsis However since the majority of bacteria that cause sepsis do not encode sialidases targeting bacterial sialidases alone would be insufficient for therapy of sepsis In order to expand the original concept to infections by microbes that do not produce sialidases we hereby hypothesize that host sialidases can also be targeted for the treatment of sepsis In support of this notion we observed that a novel sialidase inhibitor deoxy dehydro N glycolylneuraminic acid Neu Gc en conferred protection against lethal endotoxic shock Since endotoxin does not contain microbial sialidases the inhibitor has to target the host sialidase s Furthermore using mice with a targeted mutation of Neu gene among the hematopoietic cells we demonstrated a critical role for NEU in both severity of endotoxic shock and in therapeutic response to Neu Gc en These results demonstrate that NEU is a potential therapeutic target for endotoxic shock which contributes to pathogenesis of sepsis and remains largely unresponsive to current therapy Based on these exciting observations we will compare therapeutic effect of a series of newly synthesized sialidase inhibitors for their activity and selectivity for NEU The goal is to identify a lead compound tha is effective in treating endotoxic shock with minimal toxicity PUBLIC HEALTH RELEVANCE Despite availability of antibiotics the mortality and hospitalization of severe sepsis increased rapidly between and causing approximately annual deaths in US alone A major proportion of septic shock was caused by endotoxin LPS producing Gram negative bacteria Our proposed studies may provide a novel therapeutic approach for septic shock

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (2011–2020). Reported award amounts total $7,026,474. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.